Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) finished Wednesday with an addition of $0.25 to close at $24.33, an upside of 1.04 percent. An average of 3,709,540 shares of common stock have been traded in the last five days. There was a fall of -$6.52 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 1,714,065 shares traded, while the 50-day average volume stands at 2,812,470.
RYTM stock has increased by 3.22% in the last month. The company shares reached their 1-month lowest point of $20.11 on 09/07/22. With the stock rallying to its 52-week high on 09/14/22, shares of the company touched a low of $3.04 and a high of $30.98 in 52 weeks. It has reached a new high 18 times so far this year and achieved 143.79% or $14.35 in price. In spite of this, the price is down -21.47% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
34 days have passed since Rhythm Pharmaceuticals Inc. (RYTM) last reported insider trading activity. Cramer Pamela J., who is Chief Human Resources Officer, most recently acquired $13,493 shares at $24.83 per share on Aug 19. In this transaction, the insider spent $335,031. Chief Human Resources Officer, Cramer Pamela J., disposed of 901 shares at a price of $11.68 on Jul 27. The insider now owns more than $10,524 worth of shares. Prior to that, Chief Financial Officer Smith Hunter C went on to Sale 7,547 shares at $4.08 each on Jul 01. An amount of $30,792 was transacted.
Rhythm Pharmaceuticals Inc. (RYTM) stock’s beta is 2.22. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 88.59, the price-to-book (PB) ratio at 6.27.
The quick ratio of Rhythm Pharmaceuticals Inc. for the three months ended June 29 was 5.60, and the current ratio was 5.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.18 and a total debt to equity ratio of 0.18 for the quarter ending June 29. Its gross profit as reported stood at $2.56 million compared to revenue of $3.15 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Rhythm Pharmaceuticals Inc.’s return on assets was -56.30%.
For the three-month period that ended June 29, Rhythm Pharmaceuticals Inc. had $122.39 million in cash and short-term investments compared to $34.27 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$45.0 million in the quarter, while revenues of -$42.87 million were grew 197.22%. The analyst consensus anticipated Rhythm Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.95 per share, but it turned out to be -$0.89, a 6.30% surprise. For the quarter, EBITDA amounted to -$44.61 million. Shareholders own equity worth $50.72 million.
From a technical analysis perspective, let’s take a brief look at Rhythm Pharmaceuticals Inc. (RYTM) price momentum. RSI 9-day as of the close on 21 September was 50.98%, suggesting the stock is Neutral, with historical volatility in this time frame at 279.97%.
As of today, RYTM’s price is $23.86 -21.13% or -$6.52 from its 5-day moving average. RYTM is currently trading +2.57% higher than its 20-day SMA and +265.86% higher than its 100-day SMA. However, the stock’s current price level is +264.77% above the SMA50 and +175.54% above the SMA200.
The stochastic %K and %D were 35.05% and 34.06%, respectively, and the average true range (ATR) was 3.16. With the 14-day stochastic at 38.82% and the average true range at 3.00, the RSI (14) stands at 52.95%. The stock has reached -1.05 on the 9-day MACD Oscillator while the 14-day reading was at -0.48.
Goldman upgraded Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral.
What is RYTM’s price target for the next 12 months?
Analysts predict a range of price targets between $16.00 and $40.00, with a median target of $28.00. Taking a look at these predictions, the average price target given by analysts for Rhythm Pharmaceuticals Inc. (RYTM) stock is $29.25.